NCT06683937View on ClinicalTrials.gov

Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Immunocompromised PatientsSARS-CoV-2 Disease
Interventions
OTHER

Collection of data from the patient's medical file

Collection of data from the patient's medical file

Trial Locations (16)

13000

CHU Nord Marseille, Marseille

14000

CHU Caen, Caen

24000

CH Périgueux, Périgueux

30000

CHU Nîmes Caremeau, Nîmes

31000

CHU Toulouse, Toulouse

44000

CHU Nantes, Nantes

49000

CHU Angers, Angers

51100

CHU Reims, Reims

59000

CHRU Lille, Lille

68000

Hôpital Pasteur, Colmar, Colmar

75010

Hôpital Saint-Louis, Paris

75015

Hôpital Necker-Enfants Malades, Paris

75018

Hôpital Bichat, Paris

85000

CHD Vendée (La Roche sur Yon), La Roche-sur-Yon

86000

CHU Poitiers, Poitiers

97410

CHU Sud Réunion, Saint-Pierre

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06683937 - Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024 | Biotech Hunter | Biotech Hunter